Kamada Ltd. · NASDAQ:KMDA
Kamada — Q1 2026 Earnings Presentation
17 slides from Kamada's earnings presentation, May 13, 2026
Slide 1: First Quarter March 31, 2026 Investors Call
May 2026 First Quarter March 31, 2026 Investors Call NASDAQ: KMDA; TASE: KMDA.TA
Slide 2: Forward-Looking Statement
2 FORWARD- LOOKING STATEMENT This presentation is not intended to provide investment or medical advice. This presentation contains forward-looking statements, which express the current beliefs and expectations of Kamada's management. Such statements include 2026 financial guidance; roadmap for conti
Slide 3: Q1-26 Financial Performance
Q1-26 FINANCIAL PERFORMANCE 2026 OPERATIONAL AND FINANCIAL PERFORMANCE IS OFF TO A SOLID START First quarter results affected by a temporary shipment delay of a single order, subsequently delivered during April Declared cash dividend of $0.25 per share (totaling approximately $14.4M) paid on April 7
Slide 4: Annual Double-Digit Growth Trajectory
4 ANNUAL DOUBLE-DIGIT GROWTH TRAJECTORY 6 6% 18 14% 24 17% 34 21% 42 23% 50-53 ~25% 2021 2022 2023 2024 2025 2026 104 129 142 161 180 200- 205 2021 2022 2023 2024 2025 2026 ADJUSTED EBITDA US$M 53% CAGR 2026 represents annual guidance 2026 represents annual guidance REVENUES US$M 14% CAGR 2026 annua
Slide 5: Delivering on Our Commitments
DELIVERING ON OUR COMMITMENTS 5
Slide 6: Kamada's Roadmap for Continued Annual Double-Digit Profitable Growth
6 KAMADA'S ROADMAP FOR CONTINUED ANNUAL DOUBLE-DIGIT PROFITABLE GROWTH Specialty Plasma Therapies Portfolio of 6 FDA-approved products marketed in over 30 territories In-licensing Partnerships Commercialization & Distribution of third parties' biopharmaceutical products in Israel & MENA Plasma Sales
Slide 7: A Global Leader in Anti-Rabies Immune Globulin (HRIG)
$180M Total estimated U.S HRIG market size The only anti-Rabies IgG product with FDA approved label confirming safety and effectiveness in children KEDRAB/KAMRAB $54M(2025 revenues) 2026 demand is increasing; Expect to exceed $90M min. sales commitment to Kedrion for 2026 and 2027 Only 2 FDA approve
Slide 8: GLASSIA: Liquid AAT for Treatment of AAT Deficiency
8 Licensed to Takeda in the USA, Canada, Australia and New Zealand Commencing in 2022, Takeda is paying Kamada royalties, at a rate of 6% through 2040; Projected royalties in the range of $10M to $20M per year Outside the Takeda territories, GLASSIA is marketed by Kamada through a network of partner
Slide 9: CYTOGAM: CMV Immune Globulin
9 CYTOGAM $17M 2025 Revenues CMV IMMUNE GLOBULIN Growth To be supported by new clinical data demonstrating product's unique properties CYTOGAM is the only plasma-derived IgG approved in the U.S. and Canada for prophylaxis of CMV disease after Solid Organ Transplantation. CMV is the leading cause for
Slide 10: Distribution Segment Growth
10 DISTRIBUTION SEGMENT GROWTH More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market EXCLUSIVE DISTRIBUTOR IN ISRAEL FOR LEADING BIOPHARMACEUTICAL COMPANIES EXPANDING THE DISTRIBUTION SEGMENT MODEL TO THE MENA REGION Key areas:
Slide 11: Kamada Plasma: Expanding Vertical Integration & Revenue Growth
11 KAMADA PLASMA EXPANDING VERTICAL INTEGRATION & REVENUE GROWTH Collecting hyper-immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Operating three FDA Approved plasma collection centers in Texas; Houston, San Antonio and Beaumont At full collectio
Slide 12: M&A Transactions
12 M&A TRANSACTIONS AIMING TO SECURE NEW BUSINESS DEVELOPMENT AND M&A TRANSACTIONS LEVERAGING OVERALL FINANCIAL STRENGTH AND COMMERCIAL INFRASTRUCTURE Screening strategic business development opportunities to identify potential acquisition or in-licensing to accelerate long-term growth Focusing on p
Slide 13: Financial Summary Q1/26
US $ M Q1/26 Q1/25 FY/2025 DETAILS PROPRIETARY 36.2 40.0 156.2 DISTRIBUTION 9.0 4.0 24.3 TOTALREVENUES 45.2 44.0 180.5 3% YoY increase GROSS PROFIT 19.1 20.7 76.4 GROSS MARGIN 42% 47% 42% OPEX (12.2) (13.0) (50.2) NET PROFIT 4.1 4.0 20.2 4% YoY increase Adjusted EBITDA 11.6 11.6 42.0 CASH 73.1 76.3
Slide 14: Kamada - A Global Biopharmaceutical Company
KEDRAB® CYTOGAM® HEPAGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA- Approved Products 14% CAGR (from 2021) $200-205M1 2026 Revenues Guidance $50-53M1 2026 Adj. EBIDTA Guidance 4 Growth Drivers A LEADER IN SPECIALTY PLASMA THERAPIES, WITH A PORTFOLIO OF MARKETED P
Slide 15: Thank You
THANK YOU www.kamada.com NASDAQ: KMDA; TASE: KMDA.TA
Slide 16: Non-IFRS Measures – Adjusted EBITDA
NON-IFRS MEASURES – ADJUSTED EBITDA US $ M Q1/26 Q1/25 FY/2025 NET PROFIT 4.1 4.0 20.2 TAXES ON INCOME 1.3 2.6 3.3 REVALUATION OF ACQUISITION RELATED CONTINGENT CONSIDERATION 1.5 1.8 2.7 OTHER FINANCIAL EXPENSE, NET 0.0 (0.6) 0.1 AMORTIZATION OF ACQUISITION RELATED INTANGIBLE ASSETS 1.8 1.8 7.1 OTHE
Slide 17: FDA-Approved Specialty Plasma Products
17 6 FDA-APPROVED SPECIALTY PLASMA PRODUCTS KEY FOCUS ON TRANSPLANTS & RARE CONDITIONS For Important Safety Information, visit www.Kamada.com KEDRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Augmentation therapy for